Adverse events · participants with chronic prostatitis/chronic pelvic pain syndrome
1 finding from 1 review
Minor adverse events
1 finding from 1 review
Minor adverse events · people undergoing cystoscopy
Antimicrobial showed no clear difference in minor adverse events compared with placebo or no antibiotics (low certainty).
1 finding from 1 review
Minor adverse events
Desmopressin showed no clear difference in minor adverse events compared with placebo (low certainty).
1 finding from 1 review
Minor adverse events
It is very uncertain whether desmopressin changes minor adverse events compared with alpha‐blocker (very low certainty).
1 finding from 1 review
Minor adverse events
It is very uncertain whether desmopressin plus alpha‐blocker changes minor adverse events compared with alpha‐blocker (very low certainty).
1 finding from 1 review
Minor adverse events
Desmopressin plus alpha‐blocker may leads to lower minor adverse events compared with alpha‐blocker plus anticholinergic (low certainty).
1 finding from 1 review
Minor adverse events ‐ not reported
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events (grade 3 to 4) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Serious adverse events (SAEs) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Adverse events (grade 3 or 4) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Tivozanib may leads to lower serious adverse events (Grade 3 or 4) compared with sorafenib (targeted agent versus targeted agent) (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with pazopanib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
Sunitinib probably leads to higher serious adverse events (Grade 3 or 4) compared with everolimus (targeted agent versus targeted agent) (moderate certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with avelumab + axitinib (targeted agent versus immunotherapy + targeted… (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
Sunitinib showed no clear difference in serious adverse events (Grade 3 or 4) compared with pembrolizumab + axitinib (targeted agent versus immunotherapy +… (low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
It is very uncertain whether sorafenib changes serious adverse events (Grade 3 or 4) compared with sunitinib (targeted agent versus targeted agent) (very low certainty).
1 finding from 1 review
Serious adverse events (Grade 3 or 4) · Treatment‐naïve metastatic renal cell carcinoma (clear cell type)
It is very uncertain whether sunitinib changes serious adverse events (Grade 3 or 4) compared with atezolizumab + bevacizumab (targeted agent versus immunotherapy +… (very low certainty).
1 finding from 1 review